Metabolic Diseases and Down Syndrome: How Are They Linked Together?

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Mar 6

PMID 33671490

Citations 20

Authors

Manon Moreau

Soukaina Benhaddou

Rodolphe Dard

Stefania Tolu

Rim Hamze

Francois Vialard

Jamileh Movassat

Nathalie Janel

Affiliations

Soon will be listed here.

Abstract

Down syndrome is a genetic disorder caused by the presence of a third copy of chromosome 21, associated with intellectual disabilities. Down syndrome is associated with anomalies of both the nervous and endocrine systems. Over the past decades, dramatic advances in Down syndrome research and treatment have helped to extend the life expectancy of these patients. Improved life expectancy is obviously a positive outcome, but it is accompanied with the need to address previously overlooked complications and comorbidities of Down syndrome, including obesity and diabetes, in order to improve the quality of life of Down syndrome patients. In this focused review, we describe the associations between Down syndrome and comorbidities, obesity and diabetes, and we discuss the understanding of proposed mechanisms for the association of Down syndrome with metabolic disorders. Drawing molecular mechanisms through which Type 1 diabetes and Type 2 diabetes could be linked to Down syndrome could allow identification of novel drug targets and provide therapeutic solutions to limit the development of metabolic and cognitive disorders.

Citing Articles

Down syndrome and DYRK1A overexpression: relationships and future therapeutic directions.

Murphy A, Wilton S, Aung-Htut M, McIntosh C Front Mol Neurosci. 2024; 17:1391564.

PMID: 39114642 PMC: 11303307. DOI: 10.3389/fnmol.2024.1391564.

Trisomy 21-driven metabolite alterations are linked to cellular injuries in Down syndrome.

Liu J, Chen S, Huang G, Wen P, Zhou X, Wu Y Cell Mol Life Sci. 2024; 81(1):112.

PMID: 38433139 PMC: 10909777. DOI: 10.1007/s00018-024-05127-0.

Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study.

Brydges H, Onuh O, Friedman R, Barrett J, Betensky R, Lu C Am J Clin Dermatol. 2024; 25(3):473-484.

PMID: 38337127 DOI: 10.1007/s40257-024-00844-5.

Motor Skills and Executive Functions in Pediatric Patients with Down Syndrome: A Challenge for Tailoring Physical Activity Interventions.

Vandoni M, Giuriato M, Pirazzi A, Zanelli S, Gaboardi F, Pellino V Pediatr Rep. 2023; 15(4):691-706.

PMID: 37987287 PMC: 10661287. DOI: 10.3390/pediatric15040062.

Metabolic syndrome: Nutri-epigenetic cause or consequence?.

Silva-Ochoa A, Velastegui E, Falconi I, Garcia-Solorzano V, Rendon-Riofrio A, Sanguna-Soliz G Heliyon. 2023; 9(11):e21106.

PMID: 37954272 PMC: 10637881. DOI: 10.1016/j.heliyon.2023.e21106.

References

Osaili T, Attlee A, Naveed H, Maklai H, Mahmoud M, Hamadeh N . Physical Status and Parent-Child Feeding Behaviours in Children and Adolescents with Down Syndrome in The United Arab Emirates. Int J Environ Res Public Health. 2019; 16(13). PMC: 6650949. DOI: 10.3390/ijerph16132264. View

Okamoto Y, Folco E, Minami M, Wara A, Feinberg M, Sukhova G . Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res. 2007; 102(2):218-25. DOI: 10.1161/CIRCRESAHA.107.164988. View

Peiris H, Raghupathi R, Jessup C, Zanin M, Mohanasundaram D, Mackenzie K . Increased expression of the glucose-responsive gene, RCAN1, causes hypoinsulinemia, β-cell dysfunction, and diabetes. Endocrinology. 2012; 153(11):5212-21. DOI: 10.1210/en.2011-2149. View

Bergholdt R, Eising S, Nerup J, Pociot F . Increased prevalence of Down's syndrome in individuals with type 1 diabetes in Denmark: A nationwide population-based study. Diabetologia. 2006; 49(6):1179-82. DOI: 10.1007/s00125-006-0231-6. View

Nordstrom M, Paus B, Andersen L, Kolset S . Dietary aspects related to health and obesity in Williams syndrome, Down syndrome, and Prader-Willi syndrome. Food Nutr Res. 2015; 59:25487. PMC: 4317472. DOI: 10.3402/fnr.v59.25487. View

Dent R, Blackmore A, Peterson J, Habib R, Kay G, Gervais A . Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS One. 2012; 7(6):e36889. PMC: 3376099. DOI: 10.1371/journal.pone.0036889. View

Ozsu E, Ceylaner S, Onay H . Early-onset severe obesity due to complete deletion of the leptin gene in a boy. J Pediatr Endocrinol Metab. 2017; 30(11):1227-1230. DOI: 10.1515/jpem-2017-0063. View

Al-Alaiyan S, Al-Omran H, Kattan H, Sakati N, Nyhan W . Down syndrome and recurrent abortions resulting from Robertsonian translocation 21q21q. Ann Saudi Med. 1995; 15(4):391-2. DOI: 10.5144/0256-4947.1995.391. View

Kawarabayashi T, Shoji M, Sato M, Sasaki A, Ho L, Eckman C . Accumulation of beta-amyloid fibrils in pancreas of transgenic mice. Neurobiol Aging. 1996; 17(2):215-22. DOI: 10.1016/0197-4580(95)02061-6. View

10.

Epstein C . Developmental genetics. Experientia. 1986; 42(10):1117-28. DOI: 10.1007/BF01941286. View

11.

Rodrigues R, Debom G, Soares F, Machado C, Pureza J, Peres W . Alterations of ectonucleotidases and acetylcholinesterase activities in lymphocytes of Down syndrome subjects: relation with inflammatory parameters. Clin Chim Acta. 2014; 433:105-10. DOI: 10.1016/j.cca.2014.03.002. View

12.

Arcuri C, Bianchi R, Brozzi F, Donato R . S100B increases proliferation in PC12 neuronal cells and reduces their responsiveness to nerve growth factor via Akt activation. J Biol Chem. 2004; 280(6):4402-14. DOI: 10.1074/jbc.M406440200. View

13.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402(6762):656-60. DOI: 10.1038/45230. View

14.

Wisniewski K, Bobinski M . Hypothalamic abnormalities in Down syndrome. Prog Clin Biol Res. 1991; 373:153-67. View

15.

Jeremiah D, Leyshon G, Rose T, Francis H, Elliott R . Down's syndrome and diabetes. Psychol Med. 1973; 3(4):455-7. DOI: 10.1017/s0033291700054258. View

16.

Thaker V . GENETIC AND EPIGENETIC CAUSES OF OBESITY. Adolesc Med State Art Rev. 2018; 28(2):379-405. PMC: 6226269. View

17.

Rotmensch S, Goldstein I, Liberati M, Shalev J, Ben-Rafael Z, Copel J . Fetal transcerebellar diameter in Down syndrome. Obstet Gynecol. 1997; 89(4):534-7. DOI: 10.1016/S0029-7844(97)00076-8. View

18.

Hawli Y, Nasrallah M, Fuleihan G . Endocrine and musculoskeletal abnormalities in patients with Down syndrome. Nat Rev Endocrinol. 2009; 5(6):327-34. DOI: 10.1038/nrendo.2009.80. View

19.

Alexander M, Petri H, Ding Y, Wandel C, Khwaja O, Foskett N . Morbidity and medication in a large population of individuals with Down syndrome compared to the general population. Dev Med Child Neurol. 2015; 58(3):246-54. DOI: 10.1111/dmcn.12868. View

20.

Lavie L . Oxidative stress--a unifying paradigm in obstructive sleep apnea and comorbidities. Prog Cardiovasc Dis. 2008; 51(4):303-12. DOI: 10.1016/j.pcad.2008.08.003. View